Anavex Life Sciences 提交納斯達克合規計劃 解決季度報告延遲問題

false
 0001314052
 
 
 
 
 
 
 
 0001314052
 
 
 2026-07-20
 2026-07-20
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934

Date of Report (Date of earliest event
reported): July 20, 2026

 

ANAVEX LIFE SCIENCES
CORP.

(Exact name of Registrant as Specified in Its Charter)

 

Nevada
001-37606
98-0608404

(State or Other Jurisdiction
 of Incorporation)
(Commission File Number)
(IRS Employer
 Identification No.)

 
 
 
 
 

630 5th Avenue, 20th Floor

New York, NY USA
 
10111

(Address of Principal Executive Offices)
 
(Zip Code)

 

Registrant’s Telephone Number,
Including Area Code: 1-844-689-3939

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:

 

 ☐ Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

 
 

Title of each class
  
 Trading Symbol(s)
  
 

Name of each exchange on which registered

 
 Common Stock, par value $0.001 per share
  
 AVXL
  
 Nasdaq Stock Market LLC

 
 

Indicate by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act
of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐

 

  

  

 

 

Item 8.01.Other Events. 

 

On July 20, 2026, Anavex Life Sciences Corp. (the “Company”)
timely submitted its plan (the “Compliance Plan”) to the Listing Qualifications Department (the “Nasdaq Staff”)
of The Nasdaq Stock Market LLC to regain compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file
all required periodic financial reports with the Securities and Exchange Commission (“Rule 5250(c)(1)”). As previously disclosed,
on May 20, 2026, the Company received a deficiency notification letter (the “Notice”) from the Nasdaq Staff indicating that,
as a result of the Company’s inability to timely file its Quarterly Report on Form 10-Q for the quarterly period ended March 31,
2026, it is not in compliance with Rule 5250(c)(1).

 

The Notice has no immediate effect on the listing of the Company’s
common stock, which continues to trade on The Nasdaq Global Select Market under the symbol “AVXL”.

 

The Compliance Plan is currently under review by the Nasdaq Staff. If the
Compliance Plan is accepted by the Nasdaq Staff, the Nasdaq Staff may grant an extension for the Company to regain compliance. If the
Compliance Plan is not accepted by the Nasdaq Staff, the Company will have an opportunity to request a hearing on the Nasdaq Staff’s
determination before an independent Hearings Panel.

 

  

  

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 
  
  
 ANAVEX LIFE SCIENCES CORP.

 
  
  
  
  

 
 Date:
 July 20, 2026
 By: 
 /s/ Sandra Boenisch

 
  
  
  
 Sandra Boenisch, CPA, CGA

Principal Financial Officer, Treasurer